Shares of Shilpa Medicare Ltd ended nearly 1% higher on 13th February after the company announced that it has entered into a binding agreement with Switzerland-based NXI Therapeutics AG. The agreement is for a new chemical entity.
Shilpa Medicare has entered into a long-term development and commercial manufacturing agreement with NXI Therapeutics AG for a New Chemical Entity (NCE).
Under the deal, the company will develop and supply a novel drug targeting autoimmune and alloimmune disorders. It will also handle commercial supply across different territories, as informed in an exchange filing.
As part of the agreement, Shilpa Group will provide end-to-end support, including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing. Furthermore, the partnership will cover the entire journey from early development to commercialisation. This positions Shilpa as a long-term lifecycle partner for the project.
The company said the autoimmune and immune-modulation segment is one of the fastest-growing therapy areas globally. This growth is driven by rising cases and demand for targeted treatments. Moreover, by securing this mandate at an early stage, Shilpa aims to strengthen its presence in high-value, innovation-driven pipelines with strong commercial potential.
This marks the third major international development and manufacturing contract for the Karnataka-based group.
Shilpa Medicare Q3 Results
In its Q3FY26 results announced last week, Shilpa Medicare reported a 40.3% year-over-year rise in profit after tax to Rs 44.6 crore from Rs 32 crore. In addition, revenue for the December quarter increased 28% year-over-year to Rs 409 crore from Rs 319.3 crore in the same period last year.
At 3:30 PM, shares of Shilpa Medicare ended 0.90% higher at Rs 326.05 on NSE.
Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!
